GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Jan 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The GENESIS study is looking at how certain hormones produced by the heart, called Natriuretic Peptides (NP), affect the health of individuals at risk for heart and metabolic diseases. These hormones are important because lower levels are linked to a higher chance of developing diabetes and other health issues, especially among obese and Black individuals who often have lower NP levels. The study will involve exercises and glucose tests to better understand how people with these lower hormone levels can improve their health.
To participate in this study, you need to be at least 18 years old and willing to provide a genetic sample. The study is open to both men and women but not to those with certain health conditions, like severe obesity, high blood pressure, or a history of diabetes or heart diseases. If you join, you can expect to undergo some exercise and glucose challenges, which will help researchers learn more about improving health in people with lower NP levels. This study is currently recruiting participants, so it's a great opportunity to contribute to important health research!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults: Age more than or equal to 18; an equal number of Males and Females
- • Consent to the collection of genetic material
- • Willing to adhere to the study protocol
- Exclusion Criteria:
- • Age \<18, at screening.
- • BMI \>45 kg/m2.
- • Blood pressure more than 140/90 mmHg.
- • Participants who are taking more than 2 hypertension medications.
- • History of diabetes or fasting plasma glucose \>126 mg/dl or HbA1C\>=6.5% or prior treatment with antidiabetic medication.
- • Have any past or present history of cardiovascular diseases (stroke, seizure, myocardial infarction, heart failure, transient ischemic attack, angina, or cardiac arrhythmia)
- • Women who are pregnant or breastfeeding or who can become pregnant and not practicing an acceptable method of birth control during the study (including abstinence);
- • Estimated GFR \< 60 ml/min/1.73 m2; albumin creatinine ratio ≥30 mg/g
- • Hepatic Transaminase (AST and ALT) levels \>3x the upper limit of normal
- • Anemia (men, Hct \< 38%; women, Hct \<36%)
- • Inability to exercise on a treadmill
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Pankaj Arora, MD, FAHA
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials